季內，傳奇生物錄得研發開支9,550萬美元，去年同期為9,590萬美元，主要由持續西達基奧侖賽的研發活動所推動，包括在比利時進行臨床生產的啟動成本，以及傳奇生物在實體瘤項目上的持續投資。Kingsway Biotechnology (01548.HK) announced that its 47.56% holding of its joint venture Legendary Bio (LEGN.US) posted a net loss of $0.125 billion for the third quarter, compared with a loss of $62.2 million for the same period last year.
During the period, Legendary Creature's license revenue was $17.1 million, all from licensing agreements with Novara; while licensing revenue for the same period last year was $20.1 million, all from the achievement of milestones under the Younson Agreement.
Legendary Bio's third quarter collaboration revenue was $0.143 billion compared to $75.9 million in the same period last year, driven primarily by increased sales revenue from CARVYKTI related to the Younson agreement.
During the quarter, Legendary Biologics recorded US$95.5 million in R&D expenditure, compared with US$95.9 million in the same period last year, driven mainly by the ongoing R&D activities of the Stidacchio Games, including the start-up costs of clinical production in Belgium, and the ongoing investment of Legendary Biome in solid tumor projects.
As of September 30, the legendary creature's cash and cash equivalents and term deposits are $1.2 billion.
